Seminars in Hematology
Volume 40, Issue 1 , Pages 1-3 , January 2003

Chronic myeloid leukemia—Past, present, and future

References 

  1. Baccarani M, Rosto G, de Vivo A, et al.  A ramdomized study of interferon-α versus interferon-α and low dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527–1535
  2. Barthe C, Gharbi M-J, Largarde V, et al.  Mutation in the ATP binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol. 2002;119:109–111
  3. Bennett JH. Case of hypertrophy of the spleen and liver in which death took place from the suppuration of the blood. Edinburgh Med Surg J. 1845;64:413–423
  4. Bennett JH. Leucocythaemia, or White Cell Blood in Relation to the Physiology and Pathology of the Lymphatic Glandular System. Edinburgh, UK: Sutherland & Knox; 1852;
  5. Conan Doyle A: Notes on a case of leucocythaemia. Lancet 25 March:490, 1882
  6. Craigie D. Case of disease of the spleen, in which death took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J. 1845;64:400–412
  7. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7
  8. Forkner CE. Leukemia and Allied Disorders. In: New York, NY: Macmillan; 1938;p. 126–135
  9. Galton DAG. The use of myeleran and similar agents in chronic leukaemias. Lancet. 1953;1:208–213
  10. Geary CG. Historical review. The story of chronic myeloid leukaemia. Br J Haematol. 2000;110:2–11
  11. Gunz FW. The dread leukemias and the lymphomas: Their nature and their prospects. In:  Wintrobe MM editors. Blood, Pure and Eloquent. New York, NY: McGraw Hill; 1980;p. 511–546
  12. Guilhot F, Chastang C, Michallet M, et al.  Interferon alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223–229
  13. Lissauer H. Zwei Falle von Leukaemie. Berl Klin Wochenshr. 1865;2:403–404
  14. Roche-Lestinne C, Soenen-Coriunu V, Grardel-Duflos N, et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100:1014–1018
  15. Shah NP, Nicoll JM, Nagar B, et al.  Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–125
  16. Talpaz M, Kantarjian HM, McCredie KB, et al.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986;314:1065–1069
  17. Vardiman JW, Imbert M, Pierre R, et al.  Chronic myelogenous leukaemia. In:  Jaffe ES,  Harris NL,  Stein H, et al. editor. Tumours of Haematopoietic and Lymphoid Tissues. World Health Organisation Classification of Tumours. Lyon, France: AIRC Press; 2001;p. 20–26
  18. Virchow R. Weisses Blut. Frorieps Notizen. 1845;36:151–156

PII: S0037-1963(03)70037-7

Seminars in Hematology
Volume 40, Issue 1 , Pages 1-3 , January 2003

Article Tools